IMMUNITYBIO, INC.
Last · NASDAQ$9.91+0.11 (+1.12%)live · yahoo · 4h ago
Market cap$10.50B1.06B sh
P/E · TTM-10.3fwd -70.8 · eps -0.96 · loss
Beta0.03vs S&P 500
Div yield0.00%annual · TTM
52w range
$1.95$12.43
Volume29.7Msession
| Revenue | $113.3M |
|---|---|
| Operating income | $-256.0M |
| Net income | $-351.4M |
| Free cash flow | $-308.8M |
| Operating margin | -226.0% |
| Net margin | -310.2% |
| Period | 2025 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-02-23
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Rd Intensity High
Red flags
- Sbc Revenue High — SBC/Revenue 32.5%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -310.2%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -269.2%
- Cash Runway Low — Cash runway ~0.3 years
- Rd Intensity High — R&D/Revenue 183.5%
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.05
Est. revenue
59.2M
Documents
FormReporting forFiledFlags